Barclays on Merck (MRK): Terns deal shows Merck shifting toward 'more diversified onco strategy'
Tweet Send to a Friend
Barclays analyst Emily Field reiterated an Overweight rating and $140.00 price target on Merck (NYSE: MRK)The analyst commented, "Merck’s ~$6.7bn ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
